2012
A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa
Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 60: 150-157. PMID: 22395672, PMCID: PMC3360837, DOI: 10.1097/qai.0b013e318251aedd.Peer-Reviewed Original ResearchConceptsHIV-KSKing Edward VIII HospitalSymptomatic visceral diseaseActive antiretroviral therapyOpen-label trialTreatment-naive patientsTertiary referral centerAdministration of chemotherapyHAART armUrgent chemotherapyAntiretroviral therapyReferral centerVisceral diseaseTreat analysisKaposi's sarcomaHAARTChemotherapySaharan AfricaOptimal approachHIVLamivudinePatientsSarcomaStavudineNevirapine
1996
Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia
Griffith B, Brett-Smith H, Kim G, Mellors J, Chacko T, Garner R, Cheng Y, Alcabes P, Friedland G. Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia. The Journal Of Infectious Diseases 1996, 173: 1252-1255. PMID: 8627080, DOI: 10.1093/infdis/173.5.1252.Peer-Reviewed Original ResearchConceptsAntiviral effectHuman immunodeficiency virus type 1Peripheral blood mononuclear cellsImmunodeficiency virus type 1Effects of stavudineWeeks of therapyTime pointsBaseline median valuesBlood mononuclear cellsMononuclear cell culturesVirus type 1Antigen levelsMononuclear cellsPolymerase chain reactionVirus loadPlasma RNAWeek 4Baseline valuesImmune complexesStavudineVirus titersType 1Chain reactionPatientsTherapyStavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials